



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> A61B 17/00, A61K 38/18	<b>A1</b>	<b>(11) International Publication Number:</b> WO 00/47114 <b>(43) International Publication Date:</b> 17 August 2000 (17.08.00)
<b>(21) International Application Number:</b> PCT/US00/03151 <b>(22) International Filing Date:</b> 7 February 2000 (07.02.00)  <b>(30) Priority Data:</b> 60/119,939 12 February 1999 (12.02.99) US  <b>(71) Applicant:</b> COLLAGENESIS, INC. [US/US]; 500 Cummings Center, 464C, Beverly, MA 01915 (US). <b>(72) Inventor:</b> DEVORE, Dale, P.; 3 Warwick Drive, Chelmsford, MA 01824 (US). <b>(74) Agent:</b> ELBING, Karen, L.; Clark & Elbing, LLP, 176 Federal Street, Boston, MA 02110-2214 (US).		<b>(81) Designated States:</b> AU, BR, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> INJECTABLE COLLAGEN-BASED DELIVERY SYSTEM FOR BONE MORPHOGENIC PROTEINS  <b>(57) Abstract</b> <p>Disclosed herein is a method for delivering a bone morphogenic protein to a tissue site, the method involving: (a) combining the bone morphogenic protein (BMP) with a soluble collagen; and (b) administering the BMP-collagen solution to the tissue site, whereby, upon contact with the tissue, the collagen solution is converted to a collagen gel. Also disclosed herein is the use of this method for treating bone or cartilage defects, as well as useful BMP-collagen solutions.</p>		

INJECTABLE COLLAGEN-BASED DELIVERY  
SYSTEM FOR BONE MORPHOGENIC PROTEINS

5

Background of the Invention

In general, this invention relates to a delivery system for bone morphogenic proteins.

Bone is a living, dynamic tissue with substantial capacity for regeneration. Through the tightly-controlled, ongoing processes of formation and resorption, bone is involved in the regulation of serum calcium, is able to remodel in order to respond to changes in physical stress placed upon it, and is able to repair both microfractures and substantial fractures within its structure. These processes are controlled, at least in part, by the large number of growth factors present in the bone matrix. These factors include basic and acidic fibroblast growth factor, insulin-like growth factors I and II, the superfamily of transforming growth factors beta (TGF $\beta$ ), platelet derived growth factors, and bone morphogenic proteins.

Originally identified as the active components within osteoinductive extracts derived from bone, the bone morphogenic proteins, or BMPs, are now known to include a large family of proteins within the TGF $\beta$  superfamily of growth and differentiation factors. Members of the BMP family have been determined to be key signaling molecules in embryogenesis, in species ranging from *Drosophila* to humans. They are involved in delivering positional information as well as the development of hard tissues (bones and teeth) and soft tissues. When implanted into adult animals, several of the BMPs have been shown to initiate the complex cellular process resulting in the induction of bone through both the endochondral and intramembranous bone formation

-3-

12, BMP-13, and BMP-14. Preferably, the bone morphogenic protein is human BMP-2.

In a related aspect, the invention features a bone morphogenic protein (BMP)-collagen solution, whereby, upon administration to a tissue, the  
5 solution is converted to a collagen gel.

In preferred embodiments, this BMP-collagen solution is injectable; the BMP-collagen solution, upon administration to a tissue, is converted to a collagen gel within 180 seconds, more preferably, within 120 seconds, and, most preferably, within 90 seconds; the BMP-collagen solution includes a  
10 fibrillar component and forms a fibrillar matrix; the fibrillar component is at a concentration of 0.01-2.0%, more preferably, 0.1-0.8% (fibrillar collagen solids (w/v)); the BMP-collagen solution is at approximately pH 5.5-7.5, more preferably, at approximately pH 6.0-6.5; and the bone morphogenic protein is selected from the TGF $\beta$  superfamily, e.g., BMP-1, BMP-2 (BMP-2A), BMP-3  
15 (osteogenin), BMP-4 (BMP-2B), BMP-5, BMP-6, BMP-7, osteoinductive factor (OIF), BMP-8, BMP-9, BMP-10, BMP-12, BMP-13, and BMP-14. Preferably, the bone morphogenic protein is human BMP-2.

By "tissue" is meant an aggregation of similarly specialized cells in an organism, preferably, mammalian, and, most preferably, human, where the  
20 cells are exposed to the organism's extracellular fluid, and are united in performance of a function within an organism.

By "fibrillar component" is meant an insoluble fibrillar collagen component wherein the collagen molecules interact in a quarter-stagger array to form microfibrils which themselves aggregate by side-to-side and end-to-end  
25 association to form stabilized collagen fibrils. The fibrillar component exhibits a collagen solid content ranging from about 0.1-2.0% (w/v) fibrillar collagen

-5-

Detailed Description

Described herein is an injectable delivery system for BMPs which involves an initially soluble collagen which is capable of rapid polymerization. The low viscosity of the initial collagen solution allows homogeneous mixing of the introduced BMP and administration to a site by injection. The rapid polymerization characteristic allows for targeted delivery of the peptide to specific tissue sites and in concentrations which may be readily controlled through the choice of BMP concentration in the soluble collagen mixture.

Any collagen which exhibits the properties of an initially soluble state followed by rapid polymerization (preferably, within 180 seconds, more preferably, within 120 seconds, and, most preferably, within 90 seconds) may be used in the invention. Because this delivery system is optimally designed for use in mammalian systems, rapid polymerization preferably occurs at temperatures and pH's which approximate the physiological conditions of the recipient mammal. For humans, this collagen preferably polymerizes in a range of about 36°-39°C and at a pH of about 6.5-7.5.

Particularly preferred collagens for use in the invention are described in DeVore & Eiferman (U.S. Patent No. 5,492,135.) These collagens are initially soluble in form and, upon exposure to physiological fluids, undergo rapid polymerization. Such collagen solutions have been prepared at concentrations ranging from 10 mg/ml to over 70 mg/ml and at pH's ranging from about 6.0-8.0.

In addition, if desired, a fibrillar component may be added to the collagen solution to stabilize the BMP. Any appropriate fibrillar component may be utilized. Fibrillar collagen may be reconstituted from animal sources, such as bovine hide, using methods described, for example, in Borel and Randoux, *Frontiers in Matrix Biology*, Vol. 10, pages 1-58, In *Methods of*

-7-

through encouragement of new bone formation. These examples are provided for the purpose of illustrating the invention and should not be construed as limiting.

#### Preparation of Injectable Collagen-Bone Morphogenic Protein

5 For delivery of bone morphogenic protein, samples of collagen were prepared from bovine corium by the methods described in DeVore and Eiferman (U.S. Patent No. 5,492,135.) Because BMP is active at slightly acidic pH, the rapidly gelling collagen was dialyzed to pH 6.0.

For all of the following experiments, recombinant human BMP-2  
10 was used. Experiments were conducted to determine whether the addition of BMP in buffer (pH 4.5) would impede gelation or fibril formation. BMP was added to collagen at a 1:1 ratio, mixed using two syringes attached by a syringe adaptor, and then injected into a 0.8% saline solution. The still viscous mixture sank to the bottom of the solution. Gelation and fibril formation occurred  
15 within 1 minute of introduction into the saline.

The above-described collagen preparation, free of BMP, was implanted in a standard rabbit ear model. Ten day explants were examined histologically using a standard hematoxylin and eosin staining procedure as described, for example, in Luna, Specimen Preparation Pathology, pages 30-41,  
20 in *Pathology of Skin*, Eds. Farmer and Hood, Prentice Hall Int. Corp., East Norwalk, CT, 1990. The results indicated that the collagen solution had become fibrillar and had incorporated into the surrounding subcutaneous structures. There was no visible inflammation, and host fibroblasts appeared to have infiltrated the collagen matrix. These results, therefore, demonstrated the  
25 biocompatibility of the collagen preparation.

-9-

injections each, 2 intramuscularly and 2 subcutaneously. Six rats were included in each formulation group (that is, the 10% fibrillar and the 20% fibrillar component groups). Surgically-implanted sponges containing BMP and injections of BMP in buffer were used as non-collagen controls. Fourteen days following injection, the implant sites were removed for radiographic and histological analysis.

Following *in vivo* collagen-BMP injection, all injection sites demonstrated production of bone structure. Histologic evaluation of the ectopic explants showed the presence of well-defined nodules of woven bone organized into trabeculae and spicules. Polarizable collagen material was visible, arranged in a meshwork permeated by osteocytes randomly and unevenly distributed within the trabeculae. Osteoblastic activity with concomitant mineralization was intense. Collagen preparations with 20% fibrillar collagen appeared to produce denser bone after 14 days than did the 10% fibrillar collagen preparation.

In addition, the 20% fibrillar collagen formulation had greater BMP retention at the implantation site than did the 10% fibrillar formulation. Indeed, the 20% fibrillar collagen formulation retained 60% of the BMP retained using a surgically-implanted sponge (a standard treatment) and 150% of that retained following BMP-buffer injections. Comparative retention was consistent for up to nearly 200 hours post-implantation (Figure 1).

Rapidly polymerizing collagen formulations containing 20% fibrillar bovine collagen matrix and BMP (mixed with  $^{125}\text{I}$ -BMP) were also injected into bone-groove defects in rabbit forelimb long bones (80  $\mu\text{g}$  BMP/200  $\mu\text{l}$  aliquot). Surgically-implanted sponges containing BMP and injections of BMP in buffer were used as non-collagen controls. Animals were examined radiographically at 3, 24, 47, 72, 100, 170, and 190 hours post-treatment, as well as at 2, 3, and 4

-11-

Claims

1. A method for delivering a bone morphogenic protein to a tissue site, said method comprising:
  - (a) combining said bone morphogenic protein (BMP) with a soluble collagen; and
  - (b) administering said BMP-collagen solution to said tissue site, whereby, upon contact with said tissue, said collagen solution is converted to a collagen gel.
2. The method of claim 1, wherein said BMP-collagen solution is administered by injection.
3. The method of claim 1, wherein said tissue site is bone or cartilage.
4. The method of claim 3, wherein said tissue site has a defect.
5. The method of claim 4, whereby said defect is treated by delivery of said BMP to said tissue site.
6. The method of claim 1, whereby, upon administration to said tissue, said collagen solution is converted to a collagen gel within 180 seconds.
7. The method of claim 1, wherein said soluble collagen comprises a fibrillar component and forms a fibrillar matrix.

-13-

administration to said tissue, said collagen solution is converted to a collagen gel within 180 seconds.

17. The BMP-collagen solution of claim 14, wherein said solution further comprises a fibrillar component and forms a fibrillar matrix.

18. The BMP-collagen solution of claim 17, wherein said fibrillar component is at a concentration of between 0.01-2.0% (w/v) fibrillar collagen solids.

19. The BMP-collagen solution of claim 18, wherein said fibrillar component is at a concentration of approximately 0.1-0.8% (w/v) fibrillar collagen solids.

20. The BMP-collagen solution of claim 14, wherein said solution is at approximately pH 5.5-7.5.

21. The BMP-collagen solution of claim 20, wherein said solution is at approximately pH 6.0-6.5.

22. The BMP-collagen solution of claim 14 or 20, wherein said bone morphogenic protein is selected from the superfamily of TGF $\beta$  cytokines comprising BMP-1, BMP-2 (BMP-2A), BMP-3 (osteogenin), BMP-4 (BMP-2B), BMP-5, BMP-6, BMP-7 and osteoinductive factor (OIF).

23. The BMP-collagen solution of claim 22, wherein said bone morphogenic protein is human BMP-2.



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/03151

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61B 17/00; A61K 38/18  
US CL : 128/898; 522/68; 530/350

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 128/898; 522/68; 530/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EAST (US patents); DIALOG (biotech files)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,492,135 A (DEVORE et al) 20 February 1996, see entire document.	1-23
Y,E	US 6,039,762 A (MCKAY) 21 March 2000, see entire document.	1-23
Y,P	US 6,007,833 A (CHUDZIK et al) 28 December 1999, see entire document.	1-23
Y	US 5,475,052 A (RHEE et al) 12 December 1995, see entire document.	1-23
Y	US 5,413,989 A (OGAWA et al) 09 May 1995, see entire document.	1-23
Y	US 4,975,527 A (KOEZUKA et al) 04 December 1990, see entire document.	1-23

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
*U* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

18 MAY 2000

Date of mailing of the international search report

13 JUN 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ELIZABETH C. KEMMERER

Telephone No. (703) 308-0196